Avizakimab, formerly known as BOS161721, represents a promising clinical approach to treating autoimmune diseases . This monoclonal substance selectively targets IL-18 , a vital cytokine implicated in the https://denisrosr378440.blognody.com/52133660/avizakimab-a-thorough-exploration-into-bos161721-s-capability